arrow
A

Alfonso Martín Carnicero

medical oncology department
H指数:9
被引数:403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy

骨髓中自然杀伤(NK)细胞对弥漫性大B细胞淋巴瘤复发的预测价值:整合抗体依赖性细胞介导的细胞毒性(ADCC)为基础的免疫治疗

2026-02-120
OAAI
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

应答率和长期生存率在晚期黑色素瘤患者中的表现:来自前瞻性队列研究gem-1801的数据

2025-11-280
OAAI
Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes
2024-08-070
OA
the TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain (vol 24, pg 668, 2024)
2024-07-090
OAAI
The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain
2024-06-011
OAAI
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
2024-01-082
PRE
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Agamenon-seom模型预测接受基于曲妥珠单抗的一线治疗的晚期HER2-positive食管胃腺癌患者的生存

2023-03-041
OAAI
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
2022-06-010
OAAI
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
2021-06-176
OAAI
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
2021-03-028
OA
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study
2021-02-168
OA
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
2020-09-248
OAAI
Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study
2020-07-010
OAAI